|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:ATCCode
|
gptkb:B01AF01
|
|
gptkbp:availableOn
|
tablet form
|
|
gptkbp:bioavailability
|
80-100%
|
|
gptkbp:brand
|
gptkb:Xarelto
|
|
gptkbp:CASNumber
|
366789-02-8
|
|
gptkbp:contraindication
|
active pathological bleeding
severe hypersensitivity to rivaroxaban
|
|
gptkbp:developedBy
|
gptkb:Bayer
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
|
|
gptkbp:drugInteraction
|
gptkb:phenytoin
gptkb:rifampin
gptkb:clarithromycin
gptkb:ritonavir
gptkb:carbamazepine
gptkb:ketoconazole
gptkb:St._John's_Wort
|
|
gptkbp:eliminationHalfLife
|
5-9 hours (young), 11-13 hours (elderly)
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
GQSPXLAQXDMVFI-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
gptkb:C19H18ClN3O5S
|
|
gptkbp:hasPatentExpiry
|
2024 (US)
|
|
gptkbp:hasPharmacodynamics
|
inhibits free and clot-bound Factor Xa
|
|
gptkbp:hasSMILES
|
CC1=NN(C2=C1C=CC(=C2)Cl)C(=O)C3=CC=C(C=C3)S(=O)(=O)NC(=O)O
|
|
gptkbp:hasUNII
|
Y6O7T4G8P9
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB08881
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
direct Factor Xa inhibitor
|
|
gptkbp:metabolism
|
hepatic (CYP3A4, CYP2J2, CYP-independent)
|
|
gptkbp:molecularWeight
|
435.88
|
|
gptkbp:name
|
gptkb:Rivaroxaban
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
92-95%
|
|
gptkbp:PubChem_CID
|
gptkb:DB08881
gptkb:CHEMBL2010604
9875401
D08928
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
dizziness
|
|
gptkbp:status
|
true
|
|
gptkbp:target
|
gptkb:Factor_Xa
|
|
gptkbp:usedFor
|
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
prevention of venous thromboembolism after orthopedic surgery
|
|
gptkbp:bfsParent
|
gptkb:vemurafenib
|
|
gptkbp:bfsLayer
|
6
|